610 related articles for article (PubMed ID: 29564837)
1. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.
Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M;
Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837
[TBL] [Abstract][Full Text] [Related]
2. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding.
Sheikh-Taha M; Crawley RM
Am J Cardiovasc Drugs; 2020 Jun; 20(3):295-299. PubMed ID: 31709499
[TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
4. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
5. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.
Arachchillage DRJ; Alavian S; Griffin J; Gurung K; Szydlo R; Karawitage N; Laffan M
Br J Haematol; 2019 Mar; 184(5):808-816. PubMed ID: 30515764
[TBL] [Abstract][Full Text] [Related]
7. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
8. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
Sheikh-Taha M
Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
[TBL] [Abstract][Full Text] [Related]
9. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
Panos NG; Cook AM; John S; Jones GM;
Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
[TBL] [Abstract][Full Text] [Related]
10. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
[TBL] [Abstract][Full Text] [Related]
11. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.
Barzilai M; Kirgner I; Steimatzky A; Salzer Gotler D; Belnick Y; Shacham-Abulafia A; Avivi I; Raanani P; Yahalom V; Nakav S; Varon D; Yussim E; Bachar GN; Spectre G
Acta Haematol; 2020; 143(3):266-271. PubMed ID: 31610537
[TBL] [Abstract][Full Text] [Related]
12. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
[TBL] [Abstract][Full Text] [Related]
14. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
[TBL] [Abstract][Full Text] [Related]
17. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
18. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S
Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306
[TBL] [Abstract][Full Text] [Related]
19. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
[TBL] [Abstract][Full Text] [Related]
20. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
